Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum-based chemotherapy in metastatic castration-resistant prostate cancer
ChiCTR2100046039Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in prostate cancer (PCa), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: PSA remission rate. Started May 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2100046039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046039.